Verla-Pharm modernizes regulatory compliance with eQMS solutions from DHC Business Solutions

30. October 2020

Verla-Pharm Arzneimittel GmbH & Co. KG relies on the industry and solution expertise of DHC Business Solutions for the modernization and digitalization of its regulatory quality processes.

Verla-Pharm Arzneimittel GmbH & Co. KG – for short: Verla – is an independent and traditional medium-sized company based in Tutzing on Lake Starnberg. Verla is the market leader in the magnesium sector and distinguishes itself with a high level of competence in minerals. Fields of application are the treatment of magnesium and zinc deficiency, bone loss and gynecological issues. Selected herbal medicines, natural substances and high-quality dietary supplements round off the product range.

Tradition and innovation are not a contradiction at Verla. It is no surprise therefore that the continuous modernization of the entire IT landscape at Verla is of high strategic relevance. Where IoT or “Industry 4.0” solutions are already in productive use today, the digital connectivity of highly sensitive regulatory quality processes must also be guaranteed. The tools and solutions used to date are reaching their limits in terms of transparency, efficiency and increasing requirements for regulatory compliance. Verla therefore decided to replace the existing individual solution with standard software from DHC Business Solutions. The changeover is in the area of so-called controlled processes (deviationComplaint and change management) and in the controlled documents in SOP and trainingmanagement.

 Christian Paunert, Head of CGS Management at Verla, describes the associated goals this way: “We aim to standardize and further automate processes, and also to intelligently exploit the potential of the diversity of data surrounding individual production batches. To do this, we need tight integration of the DHC VISION eQMS with the ERP and MES system in use.” Expectations at Verla for the introduction of a new eQMS solution are high: “The previous paper-based workflows, for example in document control, were inefficient and prone to errors; that should change now,” he said. Christian Paunert: “We are re-thinking our quality systems and processes to create a standardized, regulatory-compliant and digital foundation for our sustainable growth.”

As part of a selection process, the decision was made in favor of the eQMS from DHC Business Solutions. The functional scope of the eQMS standard solution, its expandability, for example in the direction of quality analytics, and the proximity to the provider with short decision-making paths in the project and to downstream support were particularly convincing. Expertise in validation was also decisive, however: “What DHC Business Solutions is offering here is already convincing, even unique,” emphasizes Christian Paunert. “We not only get the software, but also the templates for end-to-endvalidation documentation, which of course has to be checked by us, extended if necessary, and finally released. With regard to validation, we receive competent advice from DHC; the consultants are familiar with the regulated environment and all know what they are talking about.”

Dr. Wolfgang Kraemer, Managing Director of DHC Business Solutions, adds: “Our unique selling point in the provider market for eQMS solutions is the SME-compliant fit for the life science industry. Medium-sized companies can be optimally serviced by DHC Business Solutions on an equal footing. They are more willing to follow best practice processes in their industry. This provides ‘time to market’ advantages that would not be possible in larger corporate structures.”

The partnership between Verla and DHC Business Solutions is therefore designed for the long term, emphasize both project partners.  

About Verla:

Verla-Pharm, one of the leading medium-sized companies in the German pharmaceutical market, has stood for expertise in mineral therapy for almost 70 years. The company has grown over the years and is a pioneer in Germany for modern mineral and vital substance therapy for the benefit of patients. For more information about Verla, please visit